ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2152

Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study

Xinjia Deng1, Yuqing Zhang2, Yilun Wang1, Na Lu3, Dongxing Xie4, Houchen Lyu5, Jie Wei6, Chao Zeng1, Guanghua Lei1 and Hui Li1, 1Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, 2Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Xiangya Hospital, Central South University, Changsha, China, 5Chinese PLA General Hospital, Department of Orthopedics, Beijing, China, 6Health Management Center, Xiangya Hospital Central South University, Changsha, China

Meeting: ACR Convergence 2023

Keywords: Arthroplasty, Mortality, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2141–2176) RA – Treatments Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and mortality. Many patients with RA underwent knee and hip replacement surgeries, i.e., knee arthroplasty and hip arthroplasty. The primary role of knee arthroplasty and hip arthroplasty is to remove the structural abnormality, leading to significant improvements in pain and function. However, the aforementioned improvements may not translate into a lower risk of all-cause mortality, one of the most important indicators for the net risk-benefit effect of any clinical treatment regimen, among patients with RA. Considering physical inactivity and use of non-steroidal anti-inflammatory drugs (NSAIDs) are major risk factors for CVD, one would anticipate that there is a potential cardioprotective advantage coupled with knee arthroplasty and hip arthroplasty as they enhance the capacity for physical activity and reduced usage of analgesics (e.g., NSAIDs). Nevertheless, the impact of these surgeries on CVD risk among patients with RA also needs to be yet confirmed. We aimed to examine the relation of knee or hip arthroplasty to the risk of all-cause mortality, CVD and VTE among patients with RA.

Methods: We included patients with RA (ages≥20 years) from the IQVIA Medical Research Data primary care database in the United Kingdom. The primary outcome was all-cause mortality. The secondary outcomes included CVD and VTE. We conducted propensity score-matched cohort studies to compare the risks of each outcome between subjects with knee arthroplasty (n=2,387) and hip arthroplasty (n=1,681), and those without knee arthroplasty (n=2,387) or hip arthroplasty (n=1,681), respectively.

Results: Subjects with knee arthroplasty had 23% lower risk of mortality than those without knee arthroplasty (HR: 0.77, 95%CI: 0.65-0.90) (Figure 1A). Similarly, a lower, albeit non-statistically significant, mortality rate was observed among subjects with hip arthroplasty than those without arthroplasty (HR: 0.87, 95%CI: 0.73-1.04) (Figure 1B). Compared with those without arthroplasty, subjects with knee or hip arthroplasty had a lower, albeit non-statistically significant, risk of CVD. The corresponding HRs were 0.86 (95%CI: 0.73-1.01) and 0.84 (95%CI: 0.69-1.02), respectively (Figure 2). Both subjects with knee or hip arthroplasty showed a higher risk of VTE than their counterparts (HR for knee arthroplasty: 1.63 (95%CI: 1.23-2.17); HR for hip arthroplasty: 2.19 (95%CI: 1.54-3.11) (Figure 3). The associations of knee and hip arthroplasty with the risks of mortality, CVD and VTE were generally consistent across strata of age and sex.

Conclusion: Our population-based cohort study provides the first evidence that knee and hip arthroplasty were associated with lower risks of mortality and CVD but increased risk of VTE among patients with RA.

Supporting image 1

Figure 1. Cumulative incidence of death among subjects with knee or hip arthroplasty compared subjects without knee or hip arthroplasty. A, subjects with knee arthroplasty compared subjects without knee arthroplasty; B, subjects with hip arthroplasty compared subjects without hip arthroplasty. KA, knee arthroplasty; HA, hip arthroplasty.

Supporting image 2

Figure 2. Cumulative incidence of cardiovascular disease among subjects with knee or hip arthroplasty compared subjects without knee or hip arthroplasty. A, subjects with knee arthroplasty compared subjects without knee arthroplasty; B, subjects with hip arthroplasty compared subjects without hip arthroplasty. KA, knee arthroplasty; HA, hip arthroplasty.

Supporting image 3

Figure 3. Cumulative incidence of venous thromboembolism among subjects with knee or hip arthroplasty compared subjects without knee or hip arthroplasty. A, subjects with knee arthroplasty compared subjects without knee arthroplasty; B, subjects with hip arthroplasty compared subjects without hip arthroplasty. KA, knee arthroplasty; HA, hip arthroplasty.


Disclosures: X. Deng: None; Y. Zhang: None; Y. Wang: None; N. Lu: None; D. Xie: None; H. Lyu: None; J. Wei: None; C. Zeng: None; G. Lei: None; H. Li: None.

To cite this abstract in AMA style:

Deng X, Zhang Y, Wang Y, Lu N, Xie D, Lyu H, Wei J, Zeng C, Lei G, Li H. Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/survival-benefits-of-knee-and-hip-arthroplasty-in-patients-with-rheumatoid-arthritis-a-general-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survival-benefits-of-knee-and-hip-arthroplasty-in-patients-with-rheumatoid-arthritis-a-general-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology